New Weight Loss Pill Shows Promise for Migraine Relief
Recent advances in weight loss medication are hinting at benefits beyond just cutting down waistlines. A new study indicates that a drug from the same family as Ozempic could potentially reduce the frequency of migraines by more than half.
Dr. Simone Braca, a neurologist at Federico II, University of Naples, noted, “Most patients reported feeling better within the first two weeks and significantly improved their quality of life.”
Migraines impact around 12% of the US population aged 12 and older.
The focus of the research is on liraglutide, a medication that simulates the GLP-1 hormone. This hormone is known to help control blood sugar, curb appetite, and aid digestion.
Liraglutide is commonly marketed as Victorza for type 2 diabetes and as Saxenda for long-term weight management in those who are obese.
In the study, researchers administered liraglutide to 31 adults struggling with obesity and chronic migraines. Each participant had previously tried at least two other migraine treatments that didn’t yield results.
After a regimen of 1.8 milligrams of liraglutide daily over three months, the number of headache days decreased from about 20 to 9 per month.
Additionally, participants experienced a significant 35-point improvement on a migraine disorder assessment test, suggesting noticeable benefits in their daily activities, whether at work, school, or socially.
Despite modest weight loss—not statistically significant—the effects appeared to persist throughout the study. Braca expressed that improvements were likely due to a reduction in cerebrospinal fluid pressure around the brain, which may play a role in triggering migraines.
“Increasing fluid pressure in the brain could be a reason for migraines,” Braca explained. “Targeting this mechanism might be beneficial for those suffering from migraines.”
While the majority of participants tolerated liraglutide well, around 38% reported mild side effects like nausea and constipation, though these did not lead anyone to discontinue treatment.
The researchers concluded that liraglutide could be effective in managing persistent migraines in obese patients, independent of weight loss. A larger follow-up study is planned to measure brain pressure more accurately.
Understanding Migraines
Migraine affects at least 39 million Americans, though the actual number could be higher due to undiagnosed cases. These debilitating headaches can bring intense throbbing pain lasting hours or even days, often accompanied by nausea, vomiting, or sensitivity to light and sound.
Studies have found that women experience migraines 2-3 times more than men.
Migraines can severely disrupt daily life, leading to missed work or school days, decreased productivity, and strained relationships.
Moreover, they are closely linked to issues such as depression and anxiety, as well as posing a higher risk for stroke and heart disease.
While genetics likely plays a significant role in migraine susceptibility, researchers have yet to pinpoint the exact causes. Currently, treatment options remain limited, with not all medications being effective for everyone, highlighting the importance of this emerging research.
“Participants were averaging 15 headache days a month, but after just three months of this treatment, that dropped by about 11 days,” said Dr. Louis Felipe Tones, a neurologist. “This change is life-altering for those living with consistent pain.” He emphasized that the discovery of this medication’s potential to lower brain pressure offers a whole new approach to treating migraines.
